Skip to main content
. Author manuscript; available in PMC: 2020 Jan 16.
Published in final edited form as: J Am Chem Soc. 2019 Jan 4;141(2):945–951. doi: 10.1021/jacs.8b10687

Figure 4.

Figure 4.

Recombinant expression can be used to conveniently modify CHaMPs with biologically active peptides. Fusion of exendin-4 to the N-terminus of ELP-Chol does not affect the self-assembly of micelles, as seen by (a) DLS and (b) cryo-TEM. c) Exendin-4 requires its free N-terminus to bind its target, GLP-1R. Cholesterol modification is compatible with the expression of exendin biological activity, resulting in a post-translationally modified recombinant drug with comparable potency to current gold standard GLP-1R agonist treatment options, such as Trulicity® and Liraglutide.